Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zymeworks (ZYME) Equity Average (2021 - 2025)

Zymeworks' Equity Average history spans 5 years, with the latest figure at $294.3 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 16.6% to $294.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $294.3 million, a 16.6% decrease, with the full-year FY2025 number at $303.6 million, down 24.43% from a year prior.
  • Equity Average hit $294.3 million in Q4 2025 for Zymeworks, down from $327.3 million in the prior quarter.
  • Over the last five years, Equity Average for ZYME hit a ceiling of $483.2 million in Q1 2023 and a floor of $201.0 million in Q3 2022.
  • Historically, Equity Average has averaged $355.4 million across 5 years, with a median of $336.4 million in 2022.
  • Biggest five-year swings in Equity Average: skyrocketed 117.21% in 2023 and later dropped 26.48% in 2025.
  • Tracing ZYME's Equity Average over 5 years: stood at $264.0 million in 2021, then rose by 27.4% to $336.4 million in 2022, then surged by 32.17% to $444.6 million in 2023, then dropped by 20.63% to $352.9 million in 2024, then dropped by 16.6% to $294.3 million in 2025.
  • Business Quant data shows Equity Average for ZYME at $294.3 million in Q4 2025, $327.3 million in Q3 2025, and $329.7 million in Q2 2025.